Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Conditions
Eyes Without Ocular Pathology
Interventions
SD-OCT
Device
Lead sponsor
Optovue
Industry
Eligibility
Not listed
Enrollment
482 participants
Timeline
2019
U.S. locations
5
States / cities
Pomona, California • Fort Lauderdale, Florida • Newark, New Jersey + 2 more
Completed Not applicable Interventional Results available

How Has Glaucoma Affected Your Quality of Life?

NCT01476644
Conditions
Glaucoma, Quality of Life
Interventions
Clinical evaluation, Performance based measures, Subjective measures of vision-related quality of life
Other
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 80 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting No phase listed Observational Accepts healthy volunteers

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

NCT06924021
Conditions
Age-Related Macular Degeneration
Interventions
Retinal Imaging
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
7
States / cities
Fargo, North Dakota • Erie, Pennsylvania • Dallas, Texas + 4 more
Completed No phase listed Observational Accepts healthy volunteers

Precision of OCT and OCTA-based Ocular Measurements

NCT03859310
Conditions
Normal Eyes and Ocular Pathology
Interventions
SD-OCT
Device
Lead sponsor
Optovue
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Marysville, Ohio
Conditions
Radiation Retinopathy
Interventions
Aflibercept
Drug
Lead sponsor
Amy C Schefler, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Conditions
Macular Edema, Epiretinal Membrane, Vitrectomy
Interventions
Dexamethasone
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
55 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
X-linked Retinoschisis, XLRS
Interventions
Dorzolamide 2% TID or brinzolamide 1% TID
Drug
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
7 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation
Drug · Device
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Beverly Hills, California • West Columbia, South Carolina • Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Comparison of OCT and OCTA-based Ocular Measurements to Those of Predicate

NCT03852485
Conditions
Normal Eyes and Eyes With Ocular Pathologies
Interventions
SD-OCT
Device
Lead sponsor
Optovue
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Newark, New Jersey • Marysville, Ohio
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Signal to Noise Ratio at Various Retinal Layers

NCT02982174
Conditions
Healthy Eyes
Interventions
3D OCT-1 Maestro, DRI OCT Triton
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Oakland, New Jersey
Completed No phase listed Observational Accepts healthy volunteers

Functionally Validated Structural Endpoints for Early AMD

NCT04112667
Conditions
Age-related Macular Degeneration, Aging
Interventions
Normal Macular Health, Early Macular Degeneration, Young Normals
Other
Lead sponsor
Cynthia Owsley
Other
Eligibility
20 Years and older
Enrollment
556 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Macular Degeneration
Interventions
0.5 mg ranibizumab
Drug
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more
Conditions
Recalcitrant Wet Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Mountain View, California
Conditions
AMD, Age- Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Bethesda, Maryland • Durham, North Carolina
Conditions
Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 38 more
Conditions
Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dorzolamide-timolol
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Age Related Macular Degeneration
Interventions
adaptive optics AO-OCT/AF instrument
Diagnostic Test
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?

NCT02622178
Conditions
Glaucoma Diagnosis
Interventions
Optical Coherence Tomography, Visual evoked potential
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Withdrawn No phase listed Observational Accepts healthy volunteers

Study Evaluating Retinal Health Monitoring System Thickness Module

NCT04428242
Conditions
Macular Edema, Macular Degeneration
Interventions
RHMS-RTM, SD-OCT
Device · Diagnostic Test
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sacramento, California
Conditions
AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Age Related Macular Degeneration
Interventions
aflibercept 2.0 mg
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Repeatability & Reproducibility
Interventions
Not listed
Lead sponsor
Optovue
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study

NCT00734487
Conditions
Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
50 Years to 85 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Bethesda, Maryland • Durham, North Carolina + 1 more